KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

doi:10.1200/JCO.2007.12.5906

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jan 2008

Lièvre Astrid, Bachet Jean-Baptiste, Boige Valérie, Cayre Anne, Le Corre Delphine, Buc Emmanuel, Ychou Marc, Bouché Olivier, Landi Bruno, Louvet Christophe, André Thierry, Bibeau Fréderic, Diebold Marie-Danièle, Rougier Philippe, Ducreux Michel, Tomasic Gorana, Emile Jean-François, Penault-Llorca Frédérique, Laurent-Puig Pierre

Abstract excerpt

PURPOSE: Cetuximab is efficient in advanced colorectal cancer (CRC). We previously showed that KRAS mutations were associated with resistance to cetuximab in 30 CRC patients. The aim of this study was to validate, in an independent larger series of 89 patients, the prognostic value of KRAS mutations on response to cetuximab and survival. PATIENTS AND METHODS: Eighty-nine metastatic CRC patients treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal

Share to Antibodies, Monoclonal, Humanized

Share to Cetuximab

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 18202412
DOI: 10.1200/JCO.2007.12.5906

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.PMID 18202412Read ↗

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies.Semantic proximity Read ↗

Lack of Relationship Between Clinical Features and KRAS Mutations in Patients with Metastatic Colorectal Cancer.Semantic proximity Read ↗

KRAS status predicts response to cetuximab for metastatic colorectal cancer.Semantic proximity Read ↗

Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.Semantic proximity Read ↗

Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group.Semantic proximity Read ↗

Clinical benefit of cetuximab and prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer: a single institution analysis.Semantic proximity Read ↗

Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.Semantic proximity Read ↗

Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.Semantic proximity Read ↗

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer.Semantic proximity Read ↗

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.Semantic proximity Read ↗

Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.